171 related articles for article (PubMed ID: 38007418)
21. Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful.
Abdelhamed W; El-Kassas M
J Viral Hepat; 2023 Feb; 30(2):148-159. PubMed ID: 36461645
[TBL] [Abstract][Full Text] [Related]
22. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
23. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
24. Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis.
Kim NJ; Vutien P; Cleveland E; Cravero A; Ioannou GN
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1723-1738.e5. PubMed ID: 35525392
[TBL] [Abstract][Full Text] [Related]
25. Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection.
Toyoda H; Yasuda S; Shiota S; Sone Y; Maeda A; Kaneoka Y; Kumada T; Tanaka J
Aliment Pharmacol Ther; 2021 Jun; 53(12):1309-1316. PubMed ID: 33896023
[TBL] [Abstract][Full Text] [Related]
26. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.
Mariño Z; Darnell A; Lens S; Sapena V; Díaz A; Belmonte E; Perelló C; Calleja JL; Varela M; Rodriguez M; Rodriguez de Lope C; Llerena S; Torras X; Gallego A; Sala M; Morillas RM; Minguez B; Llaneras J; Coll S; Carrion JA; Iñarrairaegui M; Sangro B; Vilana R; Sole M; Ayuso C; Ríos J; Forns X; Bruix J; Reig M
J Hepatol; 2019 May; 70(5):874-884. PubMed ID: 30684506
[TBL] [Abstract][Full Text] [Related]
27. Predictive models for hepatocellular carcinoma development after sustained virological response in advanced hepatitis C.
Fraile-López M; Alvarez-Navascués C; González-Diéguez ML; Cadahía V; Chiminazzo V; Castaño A; Varela M; Rodríguez M
Gastroenterol Hepatol; 2023 Dec; 46(10):754-763. PubMed ID: 36716928
[TBL] [Abstract][Full Text] [Related]
28. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
Roche B; Coilly A; Duclos-Vallee JC; Samuel D
Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
[TBL] [Abstract][Full Text] [Related]
29. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
Tayyab GUN; Rasool S; Nasir B; Rubi G; Abou-Samra AB; Butt AA
BMC Gastroenterol; 2020 Apr; 20(1):93. PubMed ID: 32252635
[TBL] [Abstract][Full Text] [Related]
30. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
Søholm J; Hansen JF; Mössner B; Røge BT; Lauersen A; Hansen JB; Weis N; Barfod TS; Lunding S; Øvrehus A; Mohey R; Thielsen P; Christensen PB
PLoS One; 2020; 15(12):e0243725. PubMed ID: 33301499
[TBL] [Abstract][Full Text] [Related]
31. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
Semmler G; Meyer EL; Kozbial K; Schwabl P; Hametner-Schreil S; Zanetto A; Bauer D; Chromy D; Simbrunner B; Scheiner B; Stättermayer AF; Pinter M; Schöfl R; Russo FP; Greenfield H; Schwarz M; Schwarz C; Gschwantler M; Alonso López S; Manzano ML; Ahumada A; Bañares R; Pons M; Rodríguez-Tajes S; Genescà J; Lens S; Trauner M; Ferenci P; Reiberger T; Mandorfer M
J Hepatol; 2022 Apr; 76(4):812-821. PubMed ID: 34871626
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?
Ahumada A; Rayón L; Usón C; Bañares R; Alonso Lopez S
World J Gastroenterol; 2021 Oct; 27(40):6737-6749. PubMed ID: 34790004
[TBL] [Abstract][Full Text] [Related]
33. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance.
Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ
Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
36. Hepatocellular carcinoma in patients cured of chronic hepatitis C: Minimal steatosis.
Rocha C; Doyle EH; Bowman CA; Fiel MI; Stueck AE; Goossens N; Bichoupan K; Patel N; Crismale JF; Makkar J; Lewis S; Perumalswami PV; Schiano TD; Hoshida Y; Schwartz M; Branch AD
Cancer Med; 2023 May; 12(9):10175-10186. PubMed ID: 37078924
[TBL] [Abstract][Full Text] [Related]
37. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
Sanduzzi-Zamparelli M; Mariño Z; Lens S; Sapena V; Iserte G; Pla A; Granel N; Bartres C; Llarch N; Vilana R; Nuñez I; Darnell A; Belmonte E; García-Criado A; Díaz A; Muñoz-Martinez S; Ayuso C; Bianchi L; Fuster-Anglada C; Rimola J; Forner A; Torres F; Bruix J; Forns X; Reig M
J Hepatol; 2022 Apr; 76(4):874-882. PubMed ID: 34856322
[TBL] [Abstract][Full Text] [Related]
38. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.
Lu MY; Yeh ML; Huang CI; Wang SC; Tsai YS; Tsai PC; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
World J Gastroenterol; 2022 Jan; 28(1):140-153. PubMed ID: 35125824
[TBL] [Abstract][Full Text] [Related]
39. Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders.
Isfordink CJ; van Erpecum KJ; Fischer K; van der Valk PR; van Vulpen LFD; Schutgens REG; Arends JE; Mauser-Bunschoten EP
Haemophilia; 2023 Jan; 29(1):106-114. PubMed ID: 36184751
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication.
Ogawa E; Toyoda H; Iio E; Jun DW; Huang CF; Enomoto M; Hsu YC; Haga H; Iwane S; Wong G; Lee DH; Tada T; Liu CH; Chuang WL; Hayashi J; Cheung R; Yasuda S; Tseng CH; Takahashi H; Tran S; Yeo YH; Henry L; Barnett SD; Nomura H; Nakamuta M; Dai CY; Huang JF; Yang HI; Lee MH; Jun MJ; Kao JH; Eguchi Y; Ueno Y; Tamori A; Furusyo N; Yu ML; Tanaka Y; Nguyen MH;
Clin Infect Dis; 2020 Dec; 71(11):2840-2848. PubMed ID: 31777940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]